Log in to save to my catalogue

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomi...

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomi...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_gup_ub_gu_se_184650

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

About this item

Full title

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

Publisher

England: Elsevier Ltd

Journal title

Lancet neurology, 2013-03, Vol.12 (3), p.233-243

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background Three small trials suggest that intravenous immunoglobulin can affect biomarkers and symptoms of mild-to-moderate Alzheimer's disease. We tested the safety, effective dose, and infusion interval of intravenous immunoglobulin in such patients. Methods We did a multicentre, placebo-controlled phase 2 trial at seven sites in the USA...

Alternative Titles

Full title

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_swepub_primary_oai_gup_ub_gu_se_184650

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_gup_ub_gu_se_184650

Other Identifiers

ISSN

1474-4422,1474-4465

E-ISSN

1474-4465

DOI

10.1016/S1474-4422(13)70014-0

How to access this item